$ARGX

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More

Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include argenx (ARGX) to Buy at UBS, DT Midstream (DTM) to Outperform at Wolfe Research, and SolarEdge (SEDG) to Buy at UBS. Downgrades include Dick's Sporting Goods (DKS) to Hold at Truist, EPAM Systems (EPAM) to Neutral at JPMorgan, and Intuit (INTU) to Neutral at Bank of America. Initiations include Atlassian (TEAM) with Outperform at RBC, JFrog (FROG) with Outperform at RBC, and Lattice Semicond

Original reporting
Published Aug 26, 2026, 11:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 12:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More — source image
Decision brief

The 30-second read

$ARGXBullishMed
01

Why it matters

These rating changes provide new actionable signals for traders, though impact varies by company.

02

Market read

Rating updates can cause short-term price moves and influence sector sentiment.

03

What to watch

Potential earnings season volatility could outweigh rating impact.

Relevance 7/10Novelty 7/10Timing: today

Background

The article compiles fresh analyst upgrades, downgrades, and initiations across several US-listed companies.

Company-level read

Ticker impact

$ARGXBullishMedium confidence
Context

ARGX was upgraded to Buy with a higher target price, indicating fresh positive analyst sentiment.

Expected impact

potential upside of 5-10%

Evidence & confidence

Analyst raised target and rating, suggesting improved outlook.

$DTMBullishMedium confidence
Context

DTM received an Outperform upgrade and a higher price target.

Expected impact

possible 3-7% gain

Evidence & confidence

Rating upgrade signals better earnings expectations.

$NEOGBullishMedium confidence
Context

NEOG was upgraded to Overweight with a modest target increase.

Expected impact

estimated 2-5% rise

Evidence & confidence

Higher rating reflects stronger growth prospects.

$SEDGBullishMedium confidence
Context

SEDG was raised to Buy with a higher target price.

Expected impact

potential 4-8% upside

Evidence & confidence

Analyst confidence increased, implying better performance.

$DKSBearishMedium confidence
Context

DKS was downgraded to Hold from Buy, lowering its target price.

Expected impact

possible 3-6% decline

Evidence & confidence

Reduced rating signals weaker outlook.

$EPAMBearishMedium confidence
Context

EPAM was cut to Neutral from Overweight, with a lower target.

Expected impact

estimated 2-5% drop

Evidence & confidence

Analyst lowered expectations.

$GDDYBearishMedium confidence
Context

GDDY was downgraded to Neutral from Overweight, target reduced.

Expected impact

possible 2-4% decline

Evidence & confidence

Weaker rating reflects concerns.

$INTUBearishMedium confidence
Context

INTU was cut to Neutral from Buy, with a lower target price.

Expected impact

potential 3-6% fall

Evidence & confidence

Analyst reduced confidence in growth.

Market effects

Analyst rating changes may affect tech and consumer discretionary sectors.

US market sentiment could shift slightly as multiple stocks receive new guidance.

Limited to US-listed equities; no direct global macro impact.

Counterpoint

Some upgrades may be premature given broader market volatility.

Key entities

  • UBS

    Provided upgrades for ARGX and SEDG.

  • Wolfe Research

    Upgraded DT Midstream.

  • Truist Financial

    Downgraded DKS and initiated AXGN.

Related articles

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$AXGNMed

Axogen (AXGN) Q3 2026 Earnings Call Transcript

Axogen (AXGN) reported Q3 2026 revenue of $75.8M, up 26.2% YoY, with Avance contributing 64% of revenue. GAAP net income was $2.3M, adjusted EBITDA $13.4M. Cash reserves totaled $350M. The company saw growth in breast, extremities, and OMF/head and neck markets, with breast growing over 50% YoY. Axogen completed the acquisition of BioCircuit, adding NerveTape to its product line. Commercial payer coverage for Avance is now at 96% of covered lives in the U.S.

$JMKEMed

Jersey Mike's Q3 Earnings Call Highlights

Jersey Mike's (JMKE) reported 43% digital sales in Q3, up from 42% YoY, with catering sales rising 17% YoY. The company opened 80 stores in Q3, bringing total stores to 3,456. Management reaffirmed 2026 outlook: 2.5%+ same-store sales growth, 8%+ net unit growth, and 20%+ adjusted EBITDA growth. The board authorized a $100M share repurchase program and a $0.35 special dividend.

$AXGNHigh

AXGN Stock Jumps As BioCircuit Deal And Bullish Targets Drive Momentum

Axogen Inc. (NASDAQ: AXGN) stock rose 27.46% on October 28, 2026, driven by clinical progress and acquisition news. The company reported Q2 2026 revenue of $69.7M, up 23.1% YoY, and raised full-year guidance to at least $279M. Analysts from Bank of America, Barclays, and Truist have set price targets between $50 and $55, citing growth prospects and recent acquisitions.

$AXGNHigh

AXGN Stock Jumps As BioCircuit Deal Fuels Bullish Outlook

Axogen Inc. (AXGN) stock surged 27.63% on October 28, 2026, following the acquisition of BioCircuit Technologies, which adds NerveTape, an FDA-cleared nerve repair device. The company reported Q2 2026 revenue of $69.7M, up 23.1% YoY, and raised full-year guidance to at least $279M with gross margins of at least 73%. Analysts from Bank of America, Barclays, Truist, and Lake Street maintain bullish ratings with price targets around $50-$55, citing strong growth and strategic acquisitions.